Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 860
- Registration Number
- NCT03075696
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Terapii Komórkowych i Chorób Wewn?trznych, Wroc?aw, Poland
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Ingalls Memorial Hospital, Harvey, Illinois, United States
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 22
- Registration Number
- NCT02987400
- Locations
- 🇦🇹
Universitätsklinik für Innere Med. III, PMU Salzburg, Salzburg, Austria
🇦🇹Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V Hämatologie und Onkologie, Innsbruck, Austria
🇦🇹UK Graz: Universitätsklinik für Innere Medizin; Klinische Abteilung für Hämatologie, Graz, Austria
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02983617
- Locations
- 🇩🇪
Evangelisches Diakoniekrankenhaus Bremen Hämatologie, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Abteilung Innere Medizin V, Heidelberg, Germany
🇩🇪Uniklinik Köln Klinik I für Innere Medizin, Köln, Germany
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT02968563
- Locations
- 🇩🇪
Ambulante Krebszentrum Schaubstraße, Frankfurt, Brandenburg, Germany
🇩🇪KH Maria Hilf-Franziskushaus, Mönchengladbach, Mönchengladbach, Germany
🇩🇪Klinikum Rechts der Isar der Technischen Universität München, München, Germany
Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 50
- Registration Number
- NCT02962401
- Locations
- 🇫🇷
Project manager, Tours, France
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT02915224
- Locations
- 🇬🇷
Attiko Hospital; Haematology Clinic, Athens, Greece
🇬🇷General Hospital G. Papanikolaou; Hematology, BMT Unit, Thessaloniki, Greece
🇬🇷AXEPA Pathology Section; A Pathology Clinic, Thessaloniki, Greece
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 86
- Registration Number
- NCT02896582
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU d'Amiens, Amiens, France
🇫🇷CH d'Avignon, Avignon, France
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 25
- Registration Number
- NCT02877550
- Locations
- 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭Universitaetsspital Basel, Basel, Switzerland
🇨🇭Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 181
- Registration Number
- NCT02867384
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT02846623
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.